Previous studies have reported an increased incidence of hypothyroidism when ICIs are combined with chemotherapy with or without antiangiogenic agents in chemotherapy-naïve, EGFR-TKI-resistant NSCLC patients (52); however, the synergistic mechanism underlying this endocrine immune-related adverse event remains unclear. This evidence concerns the gene EGFR and non-small cell lung carcinoma.